Collegium Pharmaceutical (NASDAQ:COLL) Hits New 1-Year Low - Should You Sell?

Key Points

• Collegium Pharmaceutical fell to a new 52-week low of $22.50, well below its 50-day and 200-day moving averages of $30.24 and $33.28, respectively.
• Analyst sentiment remains mixed but leans positive: the stock has a “Moderate Buy” consensus and an average price target of $48.50, despite recent downgrades and target reductions.
• The company exceeded quarterly expectations with adjusted EPS of $1.92 versus the $1.72 consensus and revenue of $199.88 million, up 6.3% year over year; major institutional investors also recently added or initiated positions.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) hit a new 52-week low during trading on Tuesday . The company traded as low as $22.50 and last traded at $22.81, with a volume of 825544 shares changing hands. The stock had previously closed at $22.75.

Wall Street Analysts Forecast Growth

COLL has been the topic of a number of analyst reports. Piper Sandler reissued a "neutral" rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Zacks Research downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Truist Financial assumed coverage on Collegium Pharmaceutical in a report on Wednesday, September 9th. They set a "buy" rating and a $49.00 price objective on the stock. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. Finally, Barclays decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a research report on Wednesday, August 19th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $48.50.

Collegium Pharmaceutical Stock Up 0.3%

The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The stock has a market capitalization of $742.69 million, a P/E ratio of 18.40 and a beta of 0.72. The stock has a fifty day moving average price of $30.24 and a 200 day moving average price of $33.28.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same quarter last year, the company earned $1.68 EPS. The firm's revenue was up 6.3% compared to the same quarter last year. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in COLL. BlackRock Inc. purchased a new position in shares of Collegium Pharmaceutical during the second quarter worth approximately $196,972,000. Jupiter Topco LLC purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at $77,743,000. California State Teachers Retirement System boosted its stake in shares of Collegium Pharmaceutical by 5,165.8% in the 2nd quarter. California State Teachers Retirement System now owns 1,550,410 shares of the specialty pharmaceutical company's stock valued at $56,125,000 after purchasing an additional 1,520,967 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock valued at $60,358,000 after purchasing an additional 377,073 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth $9,882,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company's portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium's pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.